FRANKFURT (Reuters) - Bayer's eye medication Eylea does not offer an advantage over a rival product from Novartis when treating patients with a type of diabetes-related swelling of the retina, a German healthcare cost watchdog said on Monday. The opinion issued by the German Institute for Quality and Efficiency in Health Care, or IQWiG, could affect the level of reimbursement by public insurers for Eylea in Germany. ... via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment